WO2022123592A1 - Composition pharmaceutique stable d'azilsartan médoxomil ou de sel pharmaceutiquement acceptable et procédés de préparation de celle-ci - Google Patents

Composition pharmaceutique stable d'azilsartan médoxomil ou de sel pharmaceutiquement acceptable et procédés de préparation de celle-ci Download PDF

Info

Publication number
WO2022123592A1
WO2022123592A1 PCT/IN2021/051135 IN2021051135W WO2022123592A1 WO 2022123592 A1 WO2022123592 A1 WO 2022123592A1 IN 2021051135 W IN2021051135 W IN 2021051135W WO 2022123592 A1 WO2022123592 A1 WO 2022123592A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
azilsartan
stable pharmaceutical
acceptable salt
Prior art date
Application number
PCT/IN2021/051135
Other languages
English (en)
Inventor
Ulhas Dhuppad
Arun Kumar Pandey
Roshal Lal SANDAL
Rajesh Kulkarni
Sagar Baheti
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of WO2022123592A1 publication Critical patent/WO2022123592A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • This invention relates to stable pharmaceutical composition comprising azilsartan medoxomil and processes for preparing thereof.
  • Azilsartan medoxomil a prodrug, is hydrolysed to azilsartan in the gastrointestinal tract during absorption.
  • Azilsartan is an angiotensin II receptor blocker.
  • the drug substance used in the drug product formulation is the potassium salt of azilsartan medoxomil, also known by the US accepted name of azilsartan kamedoxomil and is chemically described as (5MethyI-2-oxo4,3-dioxol-4-yl)methyI 2- ethoxy-l- ⁇ [2 , -(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)biphenyl-4yl]methyl]-lH- benzimidazole-7- carboxylate monopotassium salt. Its empirical formula is C30H23KN4O8 and its structural formula is:
  • Azilsartan kamedoxomil is a white to nearly white powder with a molecular weight of 606.62. It is practically insoluble in water and freely soluble in methanol.
  • Edarbyclor is a combination of azilsartan medoxomil (angiotensin II receptor blocker; as its potassium salt) and chlorthalidone (thiazide-like diuretic).
  • SUBSTITUTE SHEET (RULE 26) Azilsartan medoxomil, a prodrug, is hydrolyzed to azilsartan in the gastrointestinal tract during absorption. Azilsartan is an angiotensin II receptor blocker. Chlorthalidone is a monosulfamyl thiazidelike diuretic that differs chemically from thiazide diuretics by the lack of a benzothiadiazine structure.
  • Chlorthalidone is chemically described as 2-chloro-5(l-hydroxy-3-oxo-1- isoindolinyl) benzenesulfonamide. Its empirical formula is C14H11C1N2O4S. The structural formula for chlorthalidone is
  • Chlorthalidone is a white to yellowish white powder with a molecular weight of 338.76. Chlorthalidone is practically insoluble in water, in ether, and in chloroform; soluble in methanol; slightly soluble in ethanol.
  • Edarbyclor is available for oral use as tablets.
  • the tablets have a characteristic odor.
  • Each Edarbyclor tablet contains 42.68 mg of azilsartan kamedoxomil, which is equivalent to containing azilsartan medoxomil 40 mg plus 12.5 or 25 mg of chlorthalidone.
  • Each tablet of Edarbyclor also contains the following inactive ingredients: mannitol, microcrystalline cellulose, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crospovidone, magnesium stearate, hypromellose 2910, talc, titanium dioxide, ferric oxide red, polyethylene glycol 8000, and printing ink gray.
  • the angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II).
  • Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.
  • Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the active moiety, azilsartan.
  • Azilsartan blocks the vasoconstrictor and aldosteronesecreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the ATI receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis.
  • AT2 receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Azilsartan has more than a 10,000-fold greater affinity for the ATI receptor than for the AT2 receptor.
  • Blockade of the renin-angiotensin system with ACE inhibitors which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension.
  • ACE inhibitors also inhibit the degradation of bradykinin, a reaction catalyzed by ACE. Because azilsartan does not inhibit ACE (kinase II), it should not affect bradykinin levels. Whether this difference has clinical relevance is not yet known. Azilsartan does not bind to or block other receptors or ion channels known to be important in cardiovascular regulation.
  • Azilsartan kamedoxomil is available in the United States of America as EDARBI® (azilsartan medoxomil) tablets and Edarbyclor® (Azilsartan Kamedoxomil; Chlorthalidone) immediate-release oral tablets and indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
  • Edarbi is available in strengths i.e. 40 mg and 80mg and Edarbyclor is approved in the form of 40/12.5 mg and 40/25 mg (azilsartan/chlorthalidone) tablets.
  • Edarbi and Edarbyclor are indicated for the treatment of hypertension to lower blood pressure.
  • Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
  • Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
  • JNC Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
  • Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.
  • Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
  • Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents.
  • the blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of azilsartan on blood pressure.
  • US 5583141 patent discloses the compound azilsartan.
  • US 7157584 patent discloses azilsartan medoxomil or a pharmaceutically acceptable salt thereof.
  • US 7572920 patent relates to a composition
  • a composition comprising azilsartan kamedoxomil or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • US 20100016382 patent application further discloses a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising azilsartan or salt thereof, polyethylene glycol having a melting point of 20°C to 90°C and hydroxypropyl cellulose having a viscosity of about 1 to about 4 mPa as measured at 20°C using a 2% aqueous solution.
  • US 20110201658 patent application discloses a pharmaceutical package including a preparation containing azilsartan or a salt thereof, and a desiccant.
  • US 20120100093 patent application discloses a medicinal package comprising an azilsartan preparation capable of giving out smells, a packaging and a chemical absorption-type desiccant.
  • US 9066936 patent further discloses a solid pharmaceutical composition comprising azilsartan or a salt thereof and a pH control agent, wherein the pH control agent has pH of about 2 to about 5.
  • This patent teaches that azilsartan is unstable in the neutral pH range, at which pharmaceutical preparations are generally produced and solubility of azilsartan is low at a pH range where it is stable.
  • the objective of this patent was to simultaneously achieve the stability and solubility of azilsartan which is accomplished by use of a pH control agent(s) that specifically has pH of about 2 to about 5.
  • US 9169238 patent further discloses a solid preparation containing a first part containing azilsartan or a salt thereof and a pH control agent, and a second part containing a diuretic, which is obtained by separately granulating the first part and the second part.
  • This patent teaches separately granulating a first part comprising the azilsartan or a salt thereof and a pH control agent and a second part comprising chlorthalidone to give the solid preparation comprising the first part and the second part.
  • the objective of this patent was to simultaneously achieve the stability and solubility of azilsartan or a salt thereof which is accomplished by use of a pH control agent(s) that specifically has pH of about 2 to about 5.
  • WO 2014102628 patent application discloses a stable pharmaceutical composition
  • a stable pharmaceutical composition comprising azilsartan medoxomil, or a pharmaceutically acceptable salt thereof, and a polymeric carrier which is selected from the group consisting of polyvinyl pyrrolidone, copovidone, or a mixture thereof.
  • WO 2019130277A1 patent application provides pharmaceutical composition and process for the preparation of stable oral pharmaceutical compositions of azilsartan medoxomil or a pharmaceutically acceptable salt thereof, a cyclodextrin and optionally one or more pharmaceutically acceptable excipient(s).
  • the process comprises of the following steps: i) blending azilsartan medoxomil, a cyclodextrin and one or more pharmaceutically acceptable excipients, ii) dissolving a granulating agent in granulating solvent iii) granulating the blend of step i) using granulating agent prepared in step ii) iv) optionally adding one or more other pharmaceutically acceptable excipients to the blend in step iii) v) compressing the granules of step iii) or the blend of step iv) into a suitable sized tablets or filling into suitable sized capsules.
  • compositions of the present invention simultaneously achieve desired stability characteristics and dissolution profile.
  • It is an object of the present invention to provide a stable pharmaceutical composition comprising therapeutically effective amount of azilsartan medoxomil, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients optionally with second active ingredient.
  • It is an another object of the present invention to provide a stable pharmaceutical composition comprising therapeutically effective amount of azilsartan medoxomil, or a pharmaceutically acceptable salt thereof and an antioxidant and one or more pharmaceutically acceptable excipients optionally with second active ingredient.
  • Yet another aspect of the present invention provides stable pharmaceutical compositions comprising therapeutically effective amount of azilsartan medoxomil or a pharmaceutically acceptable salt thereof as a first active agent, optionally a second active agent(s), an antioxidant and one or more other pharmaceutically acceptable excipient(s).
  • It is yet another object of the present invention to provide a solid stable pharmaceutical composition of abuse-proofed, extended release pharmaceutical composition comprising azilsartan medoxomil or a pharmaceutically acceptable salt thereof, which uses a new and different beneficial formulation but is still bioequivalent to the commercially available compositions in the United States of America i.e ED ARBI® (azilsartan medoxomil) tablets and/ or EDARBYCLOR® (Azilsartan Kamedoxomil; Chlorthalidone)
  • It is an object of the present invention to provide a stable pharmaceutical composition comprising therapeutically effective amount of azilsartan medoxomil, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients optionally with second active ingredient.
  • a stable pharmaceutical composition comprising therapeutically effective amount of azilsartan medoxomil, or a pharmaceutically acceptable salt thereof and an antioxidant and one or more pharmaceutically acceptable excipients.
  • composition B A pharmaceutical composition according as in A, wherein the composition does not comprise any pH control agent(s).
  • a process for the preparation of the stable pharmaceutical composition comprising: i) granulating azilsartan medoxomil, antioxidant and one or more pharmaceutically acceptable excipients; ii) dissolving a granulating agent in granulating solvent; iii) granulating the blend of step i) using granulating agent prepared in step ii); iv) optionally adding one or more other pharmaceutically acceptable excipients to the blend in step iii); v) compressing or filling the granules of step iii) or the blend of step iv) into a suitable sized tablets or capsules.
  • composition according as in A and E, wherein the pharmaceutically acceptable excipient is selected from a group comprising of diluents/fillers, binders, disintegrants, lubricants, glidants, compression aids, colors, sweeteners, preservatives, suspending agents, film formers, flavors, used either alone or in combinations thereof.
  • composition according as in A and E comprising azilsartan medoxomil, or a pharmaceutically acceptable salt thereof as first active agent, further comprising second active agent(s), and optionally one or more other pharmaceutically acceptable excipient(s).
  • composition according as in A wherein the second active agent(s) is selected from diuretics, calcium channel antagonist or ACE inhibitors.
  • the second active agent selected is chlorthalidone as a diuretic.
  • the Stable pharmaceutical composition comprising azilsartan medoxomil, or a pharmaceutically acceptable salt thereof as first active agent, further comprising second active agent(s), and an antioxidant and optionally one or more other pharmaceutically acceptable excipient(s), wherein the process comprises: i) Granulating azilsartan medoxomil, antioxidant and one or more pharmaceutically acceptable excipients. ii) Granulating Second active and one or more pharmaceutically acceptable excipients. iii) Granules of (i) and (ii) blended and lubricated with suitable agent and compressing or filling the granules or the blend into a suitable sized tablets or capsules.
  • the Stable pharmaceutical composition according as in K wherein the pharmaceutically acceptable excipient is selected from a group comprising of diluents/fillers, binders, disintegrants, lubricants, glidants, compression aids, colors, sweeteners, preservatives, suspending agents, film formers, flavors, used either alone or in combinations thereof.
  • the pharmaceutically acceptable excipient is selected from a group comprising of diluents/fillers, binders, disintegrants, lubricants, glidants, compression aids, colors, sweeteners, preservatives, suspending agents, film formers, flavors, used either alone or in combinations thereof.
  • stable refers to chemical stability of Azilsartan in solid dosage forms wherein there is no change in assay values and dissolution and/or the total impurity remains less than 1%, when the dosage form is kept at 40°C/75% RH for 3 or 6 months.
  • the present invention provides pharmaceutical compositions comprising therapeutically effective amount of angiotensin II receptor blocker and one or more other pharmaceutically acceptable excipient(s).
  • Particularly present invention provides pharmaceutical compositions comprising therapeutically effective amount of azilsartan medoxomil as an angiotensin II receptor blocker and one or more other pharmaceutically acceptable excipient(s).
  • the "azilsartan” unless indicated otherwise in the specification refers to azilsartan in the form of free base or its pharmaceutically acceptable salt, amorphous, crystalline or any isomer or derivative, hydrate or solvate, prodrug or combinations thereof.
  • azilsartan is in the form of azilsartan medoxomil which is a prodrug of azilsartan active.
  • Azilsartan medoxomil is hydrolyzed to azilsartan in the gastrointestinal tract during absorption.
  • the term "therapeutically effective amount” is defined to mean the amount or quantity of the active drug azilsartan, which is sufficient to elicit an appreciable biological response when administered to the patient.
  • Therapeutically effective amount of azilsartan medoxomil in the respect of this invention is usually between 40 and 80 mg, usually administered once daily, although amounts outside this range and different frequencies of administration are feasible for use in therapy under prescribed medical conditions.
  • dosage forms of the present invention are useful, inter alia, in the prevention and/or treatment of hypertension and associated disorders.
  • Azilsartan medoxomil or its pharmaceutically acceptable salt(s) may be present in crystalline or amorphous forms and may include salts with inorganic bases and organic bases.
  • Inorganic bases may include, but not limited to, salts with alkali metals such as sodium or potassium, or alkaline earth metals such as calcium or magnesium.
  • Organic bases may include, but not limited to, salts of ethanolamines, tromethamine, trimethylamine, triethylamine, tertiary butylamine, pyridine and dicyclohexylamine.
  • azilsartan medoxomil is in the form of azilsartan kamedoxomil in the present invention, which is a potassium salt of azilsartan medoxomil.
  • the concentration of azilsartan medoxomil, or a pharmaceutically acceptable salt thereof, used in the pharmaceutical composition ranges from 10% w/w to 50% w/w by weight of the pharmaceutical composition.
  • An important aspect of the present invention provides compositions of azilsartan medoxomil or a pharmaceutically acceptable salt thereof that are stable. It is required that compositions comprising azilsartan as an active are chemically stable as degradation by oxidation, hydrolysis, isomerization, photolysis, polymerization, or any other method of degradation, could lead to a change in bioavailability and could also lead to toxicity. Chemical stability can be measured by a suitable, stability indicating chromatographic method for determining degradation products.
  • stable refers to the pharmaceutical composition of the present invention, when subjected to conditions of 40°C/75% RH for a period of three months or six mont results in less than 0.5% of desethyl azilsartan, desethyl azilsartan medoxomil, azilsartan medoxomil amide, ethyl azilsartan and other related substances originating from the decomposition of azilsartan medoxomil.
  • Pharmaceutical compositions of the present invention comprising azilsartan medoxomil are found to be stable. The stability of the compositions achieved without using any pH control agent which is contrary to the prior art mentioned in the earlier paragraphs and it is one of the important aspect of the present invention.
  • Another important aspect of the present invention provides a stable pharmaceutical composition
  • a stable pharmaceutical composition comprising azilsartan medoxomil or a pharmaceutically acceptable salt thereof prepared by an anhydrous granulation process comprising azilsartan medoxomil, or a pharmaceutically acceptable salt thereof.
  • Yet another important aspect of the present invention provides a stable pharmaceutical composition comprising azilsartan medoxomil or a pharmaceutically acceptable salt thereof prepared by a granulation process using a mixture of an anhydrous solvent(s) and a hydrous solvent(s).
  • Another embodiment of the present invention provides a stable pharmaceutical composition comprising azilsartan medoxomil or a pharmaceutically acceptable salt thereof prepared by a granulation process using an anhydrous granulation solvent(s) which further optionally contains a hydrous solvent(s).
  • Granulating solvent used in the present invention include, but not limited to, anhydrous, hydrous, or mixture thereof.
  • anhydrous granulation refers to a wet granulation process carried out using anhydrous solvents without the use of water.
  • Suitable anhydrous solvents include, but not limited to, acetone, methyl ethyl ketone, methyl isobutyl ketone, methanol, ethanol, isopropyl alcohol, toluene, tetrahydrofuran, chloroform, methylene chloride, or mixtures thereof.
  • acetone is preferred as an anhydrous solvent.
  • the anhydrous solvent as a wet granulating agent is used in an amount of 10% to 80% w/w.
  • the present invention also incorporates the use of a granulation process using an anhydrous solvent(s), which further optionally contains a hydrous solvent such as water.
  • the present invention further incorporates the use of a granulation process that uses a mixture of an anhydrous solvent(s) and a hydrous solvent(s). In an embodiment of the present invention, a mixture of acetone and water is a preferred granulating solvent.
  • the present invention provides stable pharmaceutical compositions comprising azilsartan medoxomil as a first active agent, optionally a second active agent(s), and optionally one or more other pharmaceutically acceptable excipient(s).
  • Second active agent(s) that can be used in the present invention include, but not limited to, antihypertensive agent(s) or a hypoglycemic agent(s).
  • Antihypertensive agents may be further selected from, but not limited to, diuretics, calcium channel blockers, and ACE inhibitors.
  • Diuretics include, but not limited to, chlorthalidone, chlorothiazide, hydrochlorothiazide, and alike or pharmaceutically acceptable salts thereof.
  • Calcium channel blockers include, but not limited to, amlodipine, felodipine, isradipine, nicardipine, nifedipine, diltiazam, verapamil or a pharmaceutically acceptable salts thereof.
  • ACE inhibitors include, but not limited to, benazepril, benazeprilat, captopril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril, or a pharmaceutically acceptable salt thereof.
  • Hypoglycemic agents include, but not limited to, repaglinide, nateglinide, glimepiride glibenclamidum, gliclazide metformin, miglitol, acarbose, pioglitazone, rosiglitazone or a pharmaceutically acceptable salt thereof.
  • the said second active is selected from diuretics that include, but not limited to, chlorthalidone, chlorothiazide and hydrochlorothiazide or pharmaceutically acceptable salts thereof.
  • the said second active agent is used in a therapeutically effective amount that is useful for the prevention and/or treatment of hypertension and associated disorders and may further shows synergistic therapeutic effect when combined with azilsartan medoxomil or a pharmaceutically acceptable salt thereof.
  • Film coats may be prepared from ready-to-make preparations which are available on the market.
  • One preferred film-coat material is OPADRY®, particularly OPADRY®white, OPADRY® blue.
  • a film coating dispersion or suspension can be prepared by using different solvents (water, alcohols, ketones, esters, chlorinated hydrocarbons), but water is preferred.
  • a specified compression force to prepare the dosage forms of the present invention is another important aspect of present invention. Applying the specified compression force to the granules or the blend prepared according to the present invention results into dosage forms having desired dissolution as well as stability profile.
  • the compression force is applied by an upper and lower punch to carry out the compression step.
  • the compression force (N) applied during the compression step of the process of the present invention is in the range of from 50 to 300 N, preferably from 50 to 200 N, more preferably from 50 to 150 N.
  • stable pharmaceutical compositions of azilsartan medoxomil or a pharmaceutically acceptable salt thereof of the present invention show desired dissolution characteristics.
  • composition(s) according to the present invention when tested for in- vitro dissolution profile, exhibits dissolution such that the amount of the drug equivalent to 85 % dissolves within 30 minutes.
  • the suitable dissolution test is selected and it is carried out in an aqueous media non-buffered or buffered to a pH range (1 to 7.8) found in the gastrointestinal tract and controlled at 37°C ( ⁇ 10°C), that maintain a physiological relevance.
  • Various dosages, such as tablets, capsules can be studied for dissolution profile, in a standard prescribed manner. When the dosage form is a tablet, typically paddles rotating at 50-75 rpm are used to test the dissolution rate of the tablets.
  • the amount of dissolved active can be determined using suitable analytical techniques such as UV or HPLC.
  • the dissolution ( in-vitro ) test in addition to its application as a quality control technique, can more preferably be used to predict the biological ( in-vivo ) performance of the tablet.
  • the dissolution test is performed in 900 mL of dissolution medium at 37° C., using USP Apparatus 2 (paddles) method at a rotation speed of 50 rpm. Samples are removed after 5, 10, 15, 20, 30, 45, and 60 minutes from test initiation and analyzed for azilsartan medoxomil. Phosphate buffer, pH 7.8 deaerated solution has been used as dissolution medium.
  • compositions or “formulation” or “dosage form” as used herein synonymously include solid dosage forms such as granules, multiunit particulate systems (MUPS), pellets, spheres, tablets, capsules, mini-tablets, layered tablets (e.g. bilayer or trilayer), beads, particles and the like; and liquid dosage forms such as solutions, suspensions, emulsions, colloids and the like, meant for oral administration.
  • solid dosage forms such as granules, multiunit particulate systems (MUPS), pellets, spheres, tablets, capsules, mini-tablets, layered tablets (e.g. bilayer or trilayer), beads, particles and the like
  • liquid dosage forms such as solutions, suspensions, emulsions, colloids and the like, meant for oral administration.
  • excipient means a pharmacologically inactive such as, but not limited to, a diluent or filler, binder, disintegrant, lubricant, glidant, surfactant, colourant or the like.
  • the excipients that are useful in preparing a pharmaceutical composition are generally safe, non-toxic and are acceptable for human use.
  • Reference to an excipient includes both one and more than one such excipients and the said excipients may be added intragranularly or extragranularly.
  • Fillers or diluents may be selected from, but not limited to, carbohydrates, confectioners sugar, compressible sugars, dextrose, dextrin, fructose, lactitol, xylitol, sorbitol, microcrystalline cellulose, mannitol, lactose, sucrose, maltose, starch, calcium carbonate, calcium sulfate, calcium hydrogen phosphate, or combinations thereof. Fillers or diluents may be used in the range of 10-90 % w/w of total weight of stable oral pharmaceutical composition.
  • Binders may be selected from, but not limited to, potato starch, wheat starch, com starch, microcrystalline cellulose, celluloses such as hydroxy propyl cellulose, hydroxy propyl methylcellulose, povidone, hydroxy ethyl cellulose, sodium carboxy methyl cellulose, natural gums like acacia, alginic acid, guar gum, liquid glucose, dextrin, povidone, syrup, polyethylene oxide, polyvinyl pyrrolidone, poly-N-vinyl amide, polyethylene glycol, gelatin, poly propylene glycol, tragacanth, or combinations thereof. Binders may be used in the range of 1-15 % w/w of total weight of stable oral pharmaceutical composition.
  • Disintegrants may be selected from, but not limited to, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, croscarmellose sodium, crospovidone, guar gum, magnesium aluminium silicate, sodium alginate, sodium starch glycolate, starches or combinations thereof. Disintegrants may be used in the range of 1-50 % w/w of total weight of stable oral pharmaceutical composition.
  • “Lubricants” may be selected from, but not limited to, aluminium stearate, zinc stearate, calcium stearate, magnesium stearate, polyethylene glycol, mineral oil, talc, hydrogenated vegetable oil, stearic acid, magnesium aluminum silicate, sodium stearyl fumarate, glyceryl behenate, sodium benzoate or mixtures thereof. Lubricant may be used in the range of 0.1 - 5 % w/w of total weight of stable oral pharmaceutical composition.
  • “Glidants” may be selected from, but not limited to, silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, calcium silicate, magnesium silicate, colloidal silicon dioxide, silicon hydrogel or mixtures thereof. Glidant may be used in the range of 0.01 - 4 % w/w of total weight of stable oral pharmaceutical composition.
  • “Surfactants” or solubilize are compounds which are capable of improving the wetting of the drug and/or enhancing the dissolution.
  • the surfactants can be selected from, but not limited to, hydrophilic surfactants or lipophilic surfactants or mixtures thereof.
  • the surfactants can be anionic, nonionic, cationic, and zwitterionic surfactants.
  • Surfactants according to the present invention are selected from, but not limited to, polyoxyethylene alkylaryl ethers such as polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether; polyethylene glycol (PEG) fatty acid esters such as PEG monolaurate, PEG dilaurate, PEG distearate, PEG dioleate; polyoxyethylene sorbitan fatty acid ester such as polysorbate 40, polysorbate 60, polysorbate 80; sorbitan fatty acid mono esters such as sorbitan monolaurate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, polyoxyethylene castor oil derivates such as polyoxyl castor oil, polyoxyl hydrogenated castor oil, sodium lauryl sulphate and the like, used either alone or in combination thereof. “Colorants” may be selected from, but not limited to, iron oxide yellow, iron oxide red, titanium dioxide or mixtures thereof
  • compositions in accordance with the present invention can be prepared either by direct compression, dry granulation like slugging or roller compaction, or by wet granulation.
  • the wet granulation method may comprise use of non- aqueous organic solvent(s) such as dichloromethane, ethanol, acetone, methylene chloride and the like, or a mixture thereof, as the granulating aid.
  • compositions in accordance with the present invention can also be prepared using a granulation method, which may comprise use of an anhydrous solvent(s), hydrous solvent(s) or mixture thereof as granulating solvent(s).
  • compositions of the present invention may be further coated with a functional or nonfunctional coating.
  • the coating composition may be comprised of pharmaceutically acceptable excipients such as coating agents, binders, plasticizers, coloring agents, and opacifiers.
  • the total weight gain after coating may be about 1% w/w to 10% w/w of the uncoated pharmaceutical composition.
  • Coating agents which are useful in coating process, may be selected from, but not limited to, water soluble polymers such as, but not limited to, polyvinylpyrrolidone or water soluble cellulose such as, but not limited to, hydroxy propyl methyl cellulose or hydroxy propyl cellulose. It may be selected from, but not limited to, soluble agents such as polysorbate 80, polysaccharides such as maltodextrin, acacia, com, sucrose, gelatin, shellac, cellulose acetate phthalate, lipids, synthetic resins, acrylic polymers, opadry, polyvinyl alcohol, copolymers of vinyl pyrrolidone, vinyl acetate or combinations thereof. These may be applied from aqueous or non- aqueous systems or combinations of aqueous and non-aqueous system as appropriate.
  • water soluble polymers such as, but not limited to, polyvinylpyrrolidone or water soluble cellulose such as, but not limited to, hydroxy
  • binders for coating include cellulose or cellulose derivatives such as, but not limited to, methylcellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and carboxymethyl cellulose sodium, and microcrystalline cellulose, alginic acid, sodium alginate and gelatin, polyvinyl pyrrolidone, copovidone, starch, pregelatinized starch, or mixtures thereof.
  • plasticizers for coating include, but not limited to, propylene glycol, triethyl citrate, tributyl citrate, dibutyl sebacate, triacetin, polyethylene glycol, diethyl phthalate, acetylated monoglycerides, or mixtures thereof.
  • opacifiers for coating include, but not limited to, titanium dioxide, talc, calcium carbonate, behenic acid, cetyl alcohol, or mixtures thereof.
  • Antitacking agents such as, but not limited to, talc, stearic acid, magnesium stearate, colloidal silicon dioxide or the like.
  • coloring agents for coating include, but not limited to, FDA approved colorants such as iron oxide, lake of tartrazine, allura red, lake of quinoline yellow, lake of erythrosine, titanium dioxide, or mixtures thereof.
  • Suitable solvents for the coating include, but not limited to, ethanol, methanol, isopropyl alcohol, methylene chloride, acetone, or mixtures thereof.
  • compositions comprising azilsartan medoxomil packed or stored into the bottle or blister pack or pouch or any corresponding packing known to a person skilled in the art in which the dosage form or the pharmaceutical compositions are packed or stored.
  • azilsartan medoxomil compositions are packed or stored into the bottle or blister pack or pouch which comprises a desiccant.
  • the term "desiccant" is referred herein to a substance used to remove or suppress or decrease the odor or to absorb moisture which prevents degradation and/or decomposition of the active agent(s).
  • the desiccant may be placed in the internal space of the package containing the composition, in an amount sufficient to remove the odorous material or to suppress or reduce the smell.
  • the desiccants are selected from, but not limited to, a synthetic zeolite, silica gel, silica-alumina, an active carbon, metallic oxide such as calcium oxide and the like used either alone or in combinations thereof.
  • azilsartan medoxomil compositions are packed or stored into the bottle or blister pack or pouch which comprises a desiccant and optionally antioxidant(s).
  • antioxidant is intended to mean an agent that inhibits oxidation, and thus is used to prevent the deterioration of preparations by oxidation due to the presence of oxygen free radicals or free metals in the composition.
  • antioxidants include, but not limited to Sodium Metabisulfite, Potassium Metabisulfite, ascorbic acid, butylated hydroxyl anisole, butylated hydroxyl toluene, propyl gallate or a mixture thereof.
  • the amount of antioxidants used in the pharmaceutical compositions of the present invention ranges from 0.01% w/w to 5% w/w.
  • An aspect of the present invention provides a method of using the compositions of the present invention comprising azilsartan medoxomil or a pharmaceutically acceptable salt thereof for the treatment of hypertension and associated disorders. Another aspect of the present invention further provides a method of using the compositions of present invention comprising therapeutically effective amount of azilsartan medoxomil or a pharmaceutically acceptable salt thereof and optionally second active agent for the treatment of hypertension and associated disorders.
  • the invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will convey the scope of the invention to those skilled in the art. Other features and embodiments of the invention will become apparent from the following examples, which are given for illustration of the invention rather than for limiting its intended scope.
  • compositions of the present invention may be prepared by the conventional processes such as wet granulation, dry granulation or direct compression as known to those skilled in the art.
  • the following examples are intended to illustrate the scope of the present invention in all its aspects but not to limit it thereto.
  • Azilsartan Kamedoxomil and Mannitol were co-sifted through required sieve.
  • Sodium Metabisulphite and Hydroxypropyl Cellulose were separately added in the water with constant stirring for suitable time.
  • the sifted materials of Azilsartan Kamedoxomil and Mannitol were loaded into Fluidized bed processor and sprayed binder solution of Hydroxypropyl Cellulose was spray on the Sodium Metabisulphite onto sifted materials. Further the material were Dried in the Fluidized bed processor until desired loss on drying is achieved. After that the material sifted through required sieves.
  • Microcrystalline cellulose and cros-carmellose sodium were passed through required sieves and added to the above blend and mix for suitable time in blender. Magnesium stearate sifted through required sieve and added to blend and lubricated for suitable time.
  • the lubricated blend was compressed with suitable size and shape followeded by coating using opadry dispersion.
  • the Azilsartan Kamedoxomil, Mannitol and Microcrystalline cellulose were sifted through suitable mesh and transferred into a fluid bed processor and Sodium Metabisulfite was dissolved into purified water. Material was granulated using the Sodium Metabisulfite solution in EBP. Dry the wet mass for suitable time. Hydroxypropyl Cellulose was dissolved into purified water. Material granulated using the Hydroxypropyl Cellulose solution. Wet granules were dried at appropriate temperature and sifted through appropriate sieve and milled through respective screen (if required) to get Azilsartan Kamedoxomil granules..
  • Chlorthalidone, Mannitol, Microcrystalline cellulose, Croscarmellose sodium and Hydroxypropyl cellulose were sifted through suitable mesh and transferred into a rapid mixer granulator and mixed in RMG for suitable time and appropriate impeller speed.
  • Sodium Lauryl Sulfate and /or Sodium hydroxide was dissolved into purified water and sifted material was granulated using the HPC solution of in RMG.
  • Wet granules were dried at appropriate temperature using FBD.
  • the Dried granules were sifted through appropriate sieve and milled through respective screen (if required) to get Chlorthalidone granules.
  • the Granules of Azilsartan Kamedoxomil and Chlorthalidone were mixed with microcrystalline cellulose, Croscarmellose Sodium in blender with suitable time and appropriate RPM. Then Lubricated for appropriate time & RPM with Magnesium stearate. Lubricated Blend was compressed into round shaped tablet followed by coating.
  • Chlorthalidone, Mannitol, Microcrystalline cellulose, Pre-gelatinized starch, Croscarmellose Sodium and Hydroxypropyl cellulose were sifted through suitable mesh and transferred into a rapid mixer granulator and mixed in RMG for suitable time and appropriate impeller speed.
  • Sodium Lauryl Sulfate and/ or Sodium Hydroxide was dissolved into purified water.
  • Material was granulated using binder solution in RMG and dried followed sifting through appropriate sieve with milling using respective screen (if required) to get Chlorthalidone granules.
  • Granules of Azilsartan Kamedoxomil and Chlorthalidone were mixed with Microcrystalline cellulose and Croscarmellose Sodium in blender bin and mixed for suitable time at appropriate RPM. Then lubricated with Magnesium stearate for appropriate time & RPM. Lubricated Blend was compressed into round shaped tablet followed by coating.

Abstract

La présente invention concerne une composition pharmaceutique stable comprenant une quantité thérapeutiquement efficace d'Azilsartan médoxomil ou d'un sel pharmaceutiquement acceptable de celui-ci en tant que premier agent actif, éventuellement un ou des seconds agents actifs, un antioxydant et un ou plusieurs autres excipients pharmaceutiquement acceptables et un procédé de préparation de celle-ci.
PCT/IN2021/051135 2020-12-08 2021-12-04 Composition pharmaceutique stable d'azilsartan médoxomil ou de sel pharmaceutiquement acceptable et procédés de préparation de celle-ci WO2022123592A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021053411 2020-12-08
IN202021053411 2020-12-08

Publications (1)

Publication Number Publication Date
WO2022123592A1 true WO2022123592A1 (fr) 2022-06-16

Family

ID=81974254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/051135 WO2022123592A1 (fr) 2020-12-08 2021-12-04 Composition pharmaceutique stable d'azilsartan médoxomil ou de sel pharmaceutiquement acceptable et procédés de préparation de celle-ci

Country Status (1)

Country Link
WO (1) WO2022123592A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159511A1 (fr) * 2011-05-23 2012-11-29 江苏恒瑞医药股份有限公司 Dispersion solide d'azilsartan, son procédé de préparation et composition pharmaceutique la comprenant
WO2013067163A1 (fr) * 2011-11-02 2013-05-10 Theravance, Inc. Inhibiteurs de la néprilysine
WO2014102628A1 (fr) * 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Composition pharmaceutique stable comprenant de l'azilsartan médoxomil
IN201721047406A (fr) * 2017-12-30 2020-06-19 Lupin Limited

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159511A1 (fr) * 2011-05-23 2012-11-29 江苏恒瑞医药股份有限公司 Dispersion solide d'azilsartan, son procédé de préparation et composition pharmaceutique la comprenant
WO2013067163A1 (fr) * 2011-11-02 2013-05-10 Theravance, Inc. Inhibiteurs de la néprilysine
WO2014102628A1 (fr) * 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Composition pharmaceutique stable comprenant de l'azilsartan médoxomil
IN201721047406A (fr) * 2017-12-30 2020-06-19 Lupin Limited

Similar Documents

Publication Publication Date Title
EP1441713B1 (fr) Comprimes de tamsulosine a liberation modifiee
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
US7741374B1 (en) Methods of use of fenofibric acid
JP2010505943A (ja) 時間治療理論に基づく循環器疾患の治療用組合せ製剤
AU2010260373A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
EP1435931A2 (fr) Forme posologique pour traiter le diabete sucre
CA2801020A1 (fr) Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide
KR101502031B1 (ko) 약제학적 복합제제
CA2644179C (fr) Composition pharmaceutique inedite comprenant une matrice de desintegration
JP2011507973A (ja) アムロジピンとバルサルタンとの医薬組成物
WO2019008485A1 (fr) Composition pharmaceutique à dose fixe à base de valsartan et de sacubitril
US20090304755A1 (en) Pharmaceutical formulation of losartan
KR20190015329A (ko) 다파글리플로진 공결정의 약학 조성물
US6333361B1 (en) Pharmaceutical composition containing zafirlukast
WO2007049291A1 (fr) Nouvelles formes solides de dosage de valsartan et d'hydrochlorothiazide
WO2019130277A1 (fr) Formulations pharmaceutiques d'azilsartan médoxomil
WO2020090970A1 (fr) Composition pharmaceutique contenant un agent antitumoral
WO2022123592A1 (fr) Composition pharmaceutique stable d'azilsartan médoxomil ou de sel pharmaceutiquement acceptable et procédés de préparation de celle-ci
CA2736257A1 (fr) Formulations galeniques de composes organiques
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
EP2571495A1 (fr) Composition pharmaceutique à libération contrôlée à base de losartan
CN102485228A (zh) 一种药物组合物及其用途
WO2009017383A2 (fr) Formulation à libération prolongée comprenant un sel d'acide de metformine
CA2642414C (fr) Composition pharmaceutique contenant de l'irbesartan a liberation rapide
WO2022036506A1 (fr) Composition et utilisation d'un inhibiteur de sglt-2 et de bloqueurs des récepteurs de l'angiotensine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21902893

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21902893

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21902893

Country of ref document: EP

Kind code of ref document: A1